Abstract
Background: Cardiovascular events can be seen in patients without classical cardiovascular risk factors, spurring the search for novel
risk markers. Biomarkers are quantifiable bodily substances that indicate disease. Biomarkers have been studied concerning
cardiovascular disease (CVD) to better understand their role in CVD development and progression. Biomarkers include Leptin, hs-CRP,
and ceruloplasmin. These biomarkers cannot diagnose cardiovascular disease alone, but they can supplement risk factors and risk
stratification.
Method: This is a case-control study that included 90 coronary artery disease patients proved by coronary angiography. Included 53
males and 37 females, ages ranging from 25–45 years, who attended Al-Sadr Teaching Hospital and Basra Oil Specialized Cardiac
Center, from December 2022 to March 2023. The patient's group were divided into a high-risk group and a low-risk group according to
the clinical presentation & numbers of coronary vessel disease. On the other hand, 90 healthy participants matched in their age and sex
to the patient’s group were included in the study. Leptin was measured by an enzyme-linked immunosorbent assay (ELISA) whereas
ceruloplasmin and hs-CRP were assayed by electrochemiluminescence immunoassay (ECLIA) using Cobas e411.
Results: Leptin and hs-CRP levels were significantly higher (p<0.05) while ceruloplasmin was significantly lower (P<0.05) in patients
with coronary artery disease compared to age-matched healthy control subjects. These novel risk markers showed no significant
statistical differences between high & low-risk groups of patients with coronary artery disease
Conclusion: There is a positive relationship between the levels of leptin, hs-CRP & risk of CVD, which might be considered as a novel
risk marker for the presence rather than severity of coronary artery disease
Main Subjects
)
